Navigation Links
Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
Date:5/5/2011

.novartis.com/product/pi/pdf/afinitor.pdf">http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf. Accessed May 2011.
  • US Food and Drug Administration. Drug Details. ZANOSAR. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed April 2011.
  • Yao, et al. One Hundred Years After "Carcinoid:" Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. Journal of Clinical Oncology. June 20 2009; vol. 26, number 18.
  • Motzer, et. al. Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma. Cancer 2010 Sep; 116(18):4256-4265.
  • National Library of Medicine and the National Institutes of Health. Neuroendocrine Tumor. Available at http://www.cancer.gov/dictionary/?CdrID=44904. Accessed April 2011.
  • American Cancer Society Detailed Guides. Gastrointestinal Carcinoid Tumors. Available at http://www.cancer.org/acs/groups/cid/documents/webcontent/003102-pdf.pdf. Accessed April 2011.
  • American Cancer Society Detailed Guides. Pancreatic Cancer. Available at http://www.cancer.org/acs/groups/cid/documents/webcontent/003131-pdf.pdf. Accessed April 2011.

  • For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis. For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.Novartis Media RelationsMedia only:Investors only:Denise Brashear

    Richard JarvisNovartis Oncology

    Novartis Corporatio
    '/>"/>

    SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
    2. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
    3. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
    4. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
    5. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
    6. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
    7. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
    8. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
    9. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
    10. Novartis to Expand Global Research Headquarters in Cambridge, MA
    11. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2014)... Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical company ... in the U.S. and XIAPEX ® in the ... will present a corporate overview at the 21 st ... The presentation will take place on Friday, September 26, ... in New York, NY . A live ...
    (Date:9/19/2014)... September 19, 2014 Aufgrund ... den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch ... PDF, verfügbar unter pharmaserialisation.com , zeigt die ... jeweils in Kraft treten. Für international ... länger um das "ob", sondern darum, "wann" sie ...
    (Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
    Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
    ... at American Society of Clinical ... Oncology Annual Meeting, PRINCETON, ... updated long-term follow-up and overall,survival (OS) results from a Phase 2 ... (DTIC) where 11.4%, or 4 of,35 patients, were still alive at ...
    ... Noted in Management of Transplant Recipients with Cancer, ... of,immunosuppression in post-transplant patients with cancer is challenging.,Clinicians ... effectively while,simultaneously monitoring the impact of chemotherapeutic agents ... improving management of such patients will be,presented today ...
    Cached Medicine Technology:Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 2Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 3Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 4Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity 2
    (Date:9/20/2014)... York, New York (PRWEB) September 20, 2014 ... power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological ... that yet another insurer has announced plans to ... statement posted on its website last month, Harrisburg, ... procedures effective November 1, 2014. The insurer said ...
    (Date:9/20/2014)... Traditionally dentists have advised their patients against drinking coffee ... is re-visiting that advice and changing his stance after considering ... have on oral health. “There’s good news and great news,” ... beneficial in protecting against gum disease, and red wine can ... was from the September 2014 issue of Boston University ...
    (Date:9/20/2014)... September 20, 2014 Earlier this week, Home ... may have had their credit card information pilfered by hackers, ... a slew of headline articles like this one ... only eye opening numbers. , “Most people tend to ... like it’s a way to score a game,” says Joe ...
    (Date:9/20/2014)... The Arizona Advanced Manufacturing ... National Manufacturing Day by opening its doors to the ... additive manufacturing labs will be offered between 10 a.m. ... Southern and Dobson campus (1833 W. Southern Ave, Mesa, ... , The AzAMI at MCC was established in the ...
    (Date:9/20/2014)... 2014 The children of Branches now ... active play they need. An empty lot at the ... Campus was transformed into a kid-designed playspace in less ... from Branches (@BranchesFL), ESPN (@TeamESPN), Disney (@CitizenDisney), area residents ... a playground is more than a playground. It’s a ...
    Breaking Medicine News(10 mins):Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 2Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 3Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 4
    ... MiLife Coaching Limited,announces the publication of their third ... weight management coaching system to boost employee,health and ... , MiLife is an ... physical activity management system. It incorporates biofeedback and,the ...
    ... season prompts tips on how to avoid most common cause ... -- If you didn,t know better, you could confuse carbon ... U.S. Environmental Protection Agency has a new fact sheet out ... deaths and 15,000 visits to the emergency room caused each ...
    ... Eklin Medical Systems, a leading,provider of digital ... and practice management software (VIA) for veterinary,care, introduced ... North American,Veterinary Conference being held in Orlando, January ... economical solution for digital imaging based on Eklin,s ...
    ... INSM ), a developer of follow-on ... dedicated to the development of, diagnosis and prevention of ... that the European Medicines Agency (EMEA) has granted Premacure ... mecasermin rinfabate, for the prevention of retinopathy of prematurity ...
    ... Varian, Inc.,(NasdaqGS: VARI) plans to release its financial ... Pacific Time (PT) on Wednesday February 4,2009. A live ... to,review those quarterly results is scheduled to follow at ... That live webcast can be accessed from Varian, ...
    ... 21 Horphag Research, exclusive worldwide,suppliers of Pycnogenol(R) ... earned the 2008 Frost & Sullivan North American ... This award, presented,last week at Frost & Sullivan,s ... Research,s efforts in conducting numerous research projects,over the ...
    Cached Medicine News:Health News:MiLife Proven to Boost Vitality of Unilever Employees Using Smart Affordable Technology 2Health News:Eklin Launches New RapidStudy(TM) CDx Digital Radiography System at NAVC 2Health News:Eklin Launches New RapidStudy(TM) CDx Digital Radiography System at NAVC 3Health News:Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants 2Health News:Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants 3Health News:Horphag Research Receives 2008 Frost & Sullivan North American Health Ingredients Excellence In Research Award 2Health News:Horphag Research Receives 2008 Frost & Sullivan North American Health Ingredients Excellence In Research Award 3
    The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
    ... Autostat™II Rheumatoid Factor IgM enzyme linked immunosorbent ... (RF IgM). Enzyme-linked immunosorbent assay method for ... Factor in human serum. The results of ... as an aid in the diagnosis of ...
    Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
    ... The GALILEI Dual Scheimpflug Analyzer is a ... and three dimensional analysis of the anterior ... Channel Scheimpflug Camera and a Placido Disk. ... technologies: Placido imaging furnishes high accuracy curvature ...
    Medicine Products: